Harris M T, Rosenthal M A, Ashley D L, Cher L
Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia.
J Clin Neurosci. 2001 Jul;8(4):325-7. doi: 10.1054/jocn.2000.0809.
Temozolomide has an evolving role in the treatment of high grade gliomas. Recent studies suggest that temozolomide is well tolerated and efficacious. This study retrospectively analysed the activity and toxicity associated with temozolomide at two Australian centres over a 24 month period. Fifty-six patients with recurrent high grade gliomas were treated with temozolomide. Patients received temozolomide orally at 150-200mg/m(2)daily, days 1-5, every 4 weeks. The median number of treatment cycles was 4 (1-12). Of the 56 patients, 15 (27%) achieved complete or partial response and 18 (32%) achieved minor response or stable disease. There were no episodes of febrile neutropenia and temozolomide was generally well tolerated. In conclusion, temozolomide is an active therapy in patients with recurrent high grade glioma and our results concord with published studies.
替莫唑胺在高级别胶质瘤的治疗中发挥着不断演变的作用。近期研究表明，替莫唑胺耐受性良好且疗效显著。本研究回顾性分析了澳大利亚两个中心在24个月期间与替莫唑胺相关的活性和毒性。56例复发性高级别胶质瘤患者接受了替莫唑胺治疗。患者在第1 - 5天口服替莫唑胺，剂量为150 - 200mg/m²，每4周重复一次。治疗周期的中位数为4（1 - 12）。56例患者中，15例（27%）达到完全或部分缓解，18例（32%）达到轻微缓解或疾病稳定。未发生发热性中性粒细胞减少症，替莫唑胺总体耐受性良好。总之，替莫唑胺是复发性高级别胶质瘤患者的一种有效治疗方法，我们的结果与已发表的研究一致。
